soloMER-Drug-Conjugates (SDCs)

Whilst the Company’s in-house effort is primarily focussed on auto-immune and anti-inflammatory conditions the qualities of the soloMER domains (small, stable, flexible etc) make them ideal for other disease opportunities such as oncology and the penetration of toxic war-heads deep into solid tumours.

Through collaboration and partnerships we are already delivering our first oncology leads and have optimised a high-efficiency and site-specific conjugation protocol for soloMER domains.  Using flexible formatting approaches we can develop, bi and tri specificities, tailor half-life with our NDure™ domain and associated platform to deliver potent oncology therapeutics including drug packed nanoparticles.
Queen’s University BelfastAlmac_